Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis (PsA) for at least 6 months~* Are candidates for phototherapy or systemic treatment of psoriasis~* Have screening laboratory test results within the study parameters~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis~* Have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or interleukin-23 (IL-23), including but not limited to ustekinumab and briakinumab~* Received conventional systemic therapies or phototherapy within the last 4 weeks~* Received biologic therapies within the last 3 months

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Ustekinumab Half-standard Dosage (Type: EXPERIMENTAL): Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
- Ustekinumab Standard Dosage (Type: EXPERIMENTAL): Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
- Placebo (Type: EXPERIMENTAL): Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).